Revelation Biosciences's EBIT per Share for the
three
months ended in Dec. 2024 was $-3.36.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-66.82.
During the past 3 years, the average EBIT per Share Growth Rate was 84.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Revelation Biosciences's EBIT per Share or its related term are showing as below:
REVB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 84.3 Med: 84.3 Max: 84.3
Current: 84.3
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Revelation Biosciences was 84.30% per year. The lowest was 84.30% per year. And the median was 84.30% per year.
REVB's 3-Year EBIT Growth Rate is ranked better than 99.18% of 1223
companies
in the Biotechnology industry
Industry Median: 5.9
vs REVB: 84.30
Revelation Biosciences EBIT per Share Historical Data
The historical data trend for Revelation Biosciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences (NAS:REVB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Revelation Biosciences EBIT per Share Related Terms
Thank you for viewing the detailed overview of Revelation Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REVB has been successfully added to your 